Pelthos Therapeutics Reports Strong ZELSUVMI Growth, Expands Dermatology Portfolio
Event summary
- ZELSUVMI net product revenue grew 28% QoQ to $9.1 million, totaling $16.2 million since launch in July 2025.
- 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers in 2025, with a 129% QoQ increase in Q4.
- Acquired XEPI and XEGLYZE, expanding dermatology portfolio to treat impetigo and head lice.
- Closed $18 million private convertible notes financing and $50 million senior secured term loan facility.
- Cash balance of $18 million as of December 31, 2025, excluding $30 million in term debt funding.
The big picture
Pelthos Therapeutics is positioning itself as a key player in the dermatology space, focusing on infectious skin conditions primarily impacting children. The strategic acquisitions of XEPI and XEGLYZE complement its lead product, ZELSUVMI, and align with the same target market. The company's financial maneuvers, including the $50 million term loan facility, indicate a focus on minimizing dilution while accelerating commercialization efforts. The biopharmaceutical industry is increasingly consolidating around specialized portfolios, and Pelthos' moves suggest a calculated approach to capturing market share in high-need dermatology segments.
What we're watching
- Revenue Growth
- Whether Pelthos can sustain the strong growth trajectory of ZELSUVMI in 2026.
- Portfolio Synergy
- How the integration of XEPI and XEGLYZE will leverage existing commercial relationships.
- Financial Strategy
- The pace at which Pelthos can achieve positive cash flow and net income.
Related topics